Massachusetts Medical Society, New England Journal of Medicine, 22(373), p. 2117-2128
Full text: Download
The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.